Trial Profile

A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jun 2025 According to a Jasper Therapeutics media release, data from this study will be presented at the EAACI Congress 2025, to be held June 13-16, 2025 in Glasgow, United Kingdom.
21 May 2025 Status changed from recruiting to active, no longer recruiting.
12 May 2025 According to a Jasper Therapeutics media release, the company has completed enrollment in the third and final cohort (180mg) of the study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com